At Project Purple, we understand how hard it can be to manage medical bills during and after pancreatic cancer treatment. We are proud to announce that our Patient Financial Aid Program is expanding to support Canadian residents seeking treatment at U.S. cancer centers.
This program assists with medical and everyday expenses so patients can focus on their fight. At Project Purple, we have never denied financial assistance to qualified patients. Financial aid was formerly only for U.S. residents treated in the U.S.
Through this expansion, Patient Financial Aid will now cover medical expenses billed to a U.S. medical facility. Patients must be currently enduring chemotherapy, radiation, or surgery, or be in remission but still receiving ongoing care related to pancreatic cancer.
“We’re listening to the community, and we’ve had people in this situation apply. So we want to provide that support to even more people,” CEO and Founder Dino Verrelli said.
Our Patient Financial Aid Program has served over 1,500 families in need of financial support. We have provided over $1,500,000 in patient aid and are expecting to donate an additional $500,000 this year. This year’s payout will be 25% more than last year, a record for Project Purple.
“We’re supporting Canadian residents coming here for quality treatment or second opinions in U.S. cancer facilities,” Verrelli said. “What we’re doing here has no borders, and we’re glad to be expanding that care to help more patients access the treatment they need.”
If you or a loved one is suffering from pancreatic cancer, visit https://www.projectpurple.org/patients-families/patient-financial-aid/ for more information regarding our Patient Financial Aid Program opportunities and application process.
About Project Purple
Founded in 2010, Project Purple is committed to creating a world without pancreatic cancer while improving care and outcomes for patients and their families. Since its inception, the organization has funded over $4 million in research, with a strong emphasis on early detection initiatives, including PRECEDE, the world’s largest high-risk consortium for genetic mutations linked to pancreatic cancer.
Project Purple’s research support also includes foundational funding for Hartford HealthCare’s High Risk Pancreatic Cancer Screening Program, multiple studies at Duke University School of Medicine, and numerous other groundbreaking projects.
To learn more about Project Purple, visit projectpurple.org/about.
